WANT TO LEARN MORE ABOUT OUR PRODUCTS OR SOLUTIONS?

  • Omni Legend 32 cm increases small lesion detectability 16% on average and up to 20%, as compared to Discovery MI 25 cm with matched scan time/injected dose, as demonstrated in phantom testing using a model observer with 4 mm lesions; average of different reconstruction methods.
  • Revolution™ Aspire is not 510(k) cleared by the US FDA and is not yet CE marked. It is not available for sale in the United States or the EU and is also not commercially available in all markets.
  • SIGNA™ Victor is not 510(k) cleared at FDA and is not yet CE marked.
  • StarGuide, OMNI Legend and MyoSPECT is commercially available in UAE, Bahrain and Turkey.
  • Service Shop is available in Saudi Arabia and Egypt within Emerging Markets
  • Commercial availability of GE Healthcare medical systems is subject to meeting local requirements in a given country or region. Contact a GE Healthcare Representative for more information.

JB05927XE